Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Relationship of HCV RNA responses to CPG 10101, A TLR9 Agonist: Pharmacodynamics and patient characteristics

John McHutchinson, Duke Univeristy, Durham, NC; Bruce Bacon, St. Louis University Hospital, St. Louis, MO; Stuart C. Gordon, Henry Ford Hospital, Detroit, MI; Eric Lawitz, Alamo Medical Research, San Antonio, TX; Michell Shiffman, Medical College of Virginia, Richmond, VA; Nezam H. Afdhal, Beth Israel Deaconess Medical Center, Boston, MA; Ira Jacobson, Cornell University, New York, NY; Andrew Muir, Duke Univeristy, Duram, NC; Susan Elfer, Coley Pharmaceutical Group, Ottawa, Canada; Mohammed Al-Adhami, Coley Pharmaceuticals Group, Wellesley, MA; Heather Davis, Coley Pharmaceutical Group, Ottawa, Canada; Tess Schmalbach, Coley Pharmaceutical Group, Wellesley, MA. Relationship of HCV RNA responses to CPG 10101, A TLR9 Agonist: Pharmacodynamics and patient characteristics. Hepatology. 2005; 42(4):75A.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.